Depressive symptoms in a treated multiple sclerosis cohort

Multiple Sclerosis

Volumn 9, Issue 6, 2003, Pages 616-620

  Patten, Scott B ^a   Fridhandler, Shanika ^a   Beck, Cynthia A ^a   Metz, Luanne M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Depression; Depressive symptoms; Glatiramer acetate; Interferons; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG CHOICE; DRUG COST; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; RATING SCALE; REIMBURSEMENT; SYMPTOM;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALBERTA; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERFERON-BETA; LOGISTIC MODELS; MALE; MULTIPLE SCLEROSIS; PEPTIDES; PREVALENCE;

EID: 0344098859     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms960oa     Document Type: Article

References (24)

1. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorders and multiple sclerosis. Arch Neurol 1987; 44: 376-378.
2. Minden SL, Orav J, Reich P. Depression im multiple sclerosis. Gen Hosp Psychiatry 1987; 9: 426-34.
3. Pattern SB, Metz LM, Reimer MM. Biopsychosocial correlates of major depression in a multiple sclerosis population. Mult Scler 2000; 6: 115-20.
4. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IML, Eisen K et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-32.
5. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon β1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531-33.
6. Sadovnick AD, Eisen K, Ebers K, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-96.
7. Stenager EN, Stenager E, Koch-Henriksen N, Bronnum-Hansen H, Hyllested K, Jensen K et al. Suicide and multiple sclerosis: An epidemiological investigation. J Neurol Neurosurg Psychiatry 1992; 55: 542-45.
8. Klapper JA. Interferon beta treatment of multiple sclerosis. Neurology 1994; 44: 188.
9. European Study Group on Interferon β1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
10. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
11. Prisms Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
12. Patten SB, Metz LM. Interferon β-1a and depression in relapsing-remitting multiple sclerosis: An analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7: 243-48.
13. Patten SB, Metz LM. Interferon β-1a and depression in secondary progressive ms: Data from the SPECTRIMS Trial. Neurology 2002; 59: 746.
14. McDowell I, Newell C. Measuring Health, a Guide to Rating Scales and Questionnaires. New York: Oxford University Press, 1996.
15. Mohr DC, Goodkin DE, Likosky W, Beutler L, Gatto N, Langan MK. Identification of Beck Depression Inventory items related to multiple sclerosis. J Behav Med 1997; 20: 407-14.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability scale (EDSS). Neurology 1983; 33: 1444-52.
17. Vickery BG, Hays RD, Harooni R, Myers LW, Dixon AK. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.
18. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis: 1. Frequency, patterns, and prediction. Can J Neurol Sci 1994; 21: 9-14.
19. Kurtzke JF. Disability rating scales in multiple sclerosis. Ann NY Acad Sci 1984; 436: 347-60.
20. Mellerup E, Fog T, Raun N, Colville P, De Rham B, Hannah B et al. The socio-economic scale. Acta Neurol Scand 1981; 64(Suppl 87): 130-38.
21. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Measure 1977; 1: 385-401.
22. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations: A validation study. Am J Epidemiol 1977; 106: 203-14.
23. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones B et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577-80.
24. Neutel CI. A new, 'user-friendly' terminology for confounding by indication in the study of adverse drug reactions. Post Marketing Surveillance 1993; 7: 363-69.